Abstract
Study design:
Randomized, double-blind, placebo-controlled, two-period crossover.
Objectives:
To evaluate the efficacy and safety of arbaclofen placarbil (AP) in patients with spasticity secondary to spinal cord injury (SCI).
Setting:
United States and Canada.
Methods:
Patients received extended-release AP tablets 10, 20 or 30 mg every 12 h in one of two AP/placebo sequences, with 26 days of each treatment. The primary analysis compared Ashworth scale assessments of muscle tone between AP and placebo for the muscle group with maximum baseline Ashworth score. Secondary endpoints included a patient-rated Severity of Spasticity Scale.
Results:
In the primary analysis, AP significantly improved Ashworth scores compared with placebo over the dosing interval: least-squares mean reduction versus placebo was 0.60 for AP 20 mg (P=0.0059) and 0.88 for AP 30 mg (P=0.0007). The difference was significant for the pre-morning dose time point, 12 h after the prior evening dose, indicating that efficacy was maintained throughout the dosing interval. Treatment differences for AP 10 mg versus placebo were not significant. Severity of Spasticity ratings were significantly reduced for the combined 20/30-mg group versus placebo (P=0.018). No statistically significant differences between AP and placebo were observed for muscle strength. AP-related AEs were generally mild to moderate in intensity, and none led to early withdrawal or were serious.
Conclusion:
AP was well tolerated at all investigated dosages and, when administered at doses of 20 or 30 mg twice daily, was efficacious in reducing spasticity due to SCI.
Similar content being viewed by others
Log in or create a free account to read this content
Gain free access to this article, as well as selected content from this journal and more on nature.com
or
References
Elbasiouny SM, Moroz D, Bakr MM, Mushahwar VK . Management of spasticity after spinal cord injury: current techniques and future directions. Neurorehabil Neural Repair 2010; 24: 23–33.
National SCI Statistical Center. National Spinal Cord Injury Statistical Center. Spinal cord injury facts and figures at a glance. The National SCI Statistical Center Web Site. Available at https://www.nscisc.uab.edu/public_content/pdf/Facts%20and%20Figures%20at%20a%20Glance%202010.pdf. Accessed November 15, 2010.
Adams MM, Hicks AL . Spasticity after spinal cord injury. Spinal Cord 2005; 43: 577–586.
Rizzo MA, Hadjimichael OC, Preiningerova J, Vollmer TL . Prevalence and treatment of spasticity reported by multiple sclerosis patients. Mult Scler 2004; 10: 589–595.
Young RR . Spasticity: a review. Neurology 1994; 44: S12–S20.
Misgeld U, Bijak M, Jarolimek W . A physiological role for GABAB receptors and the effects of baclofen in the mammalian central nervous system. Prog Neurobiol 1995; 46: 423–462.
Lal R, Sukbuntherng J, Tai EH, Upadhyay S, Yao F, Warren MS et al. Arbaclofen placarbil, a novel R-baclofen prodrug: improved absorption, distribution, metabolism, and elimination properties compared with R-baclofen. J Pharmacol Exp Ther 2009; 330: 911–921.
Schwarz Pharma. Kemstro™ (Baclofen Orally Disintegrating Tablets) (Prescribing Information). Schwarz Pharma: Milwaukee, WI, 2004.
Smith CR, LaRocca NG, Giesser BS, Scheinberg LC . High-dose oral baclofen: experience in patients with multiple sclerosis. Neurology 1991; 41: 1829–1831.
Medtronic Inc. Lioresal® Intrathecal (Baclofen Injection) (Prescribing Information). Medtronic Inc: Minneapolis, MI, 2010.
Albright AL, Barry MJ, Fasick MP, Janosky J . Effects of continuous intrathecal baclofen infusion and selective posterior rhizotomy on upper extremity spasticity. Pediatr Neurosurg 1995; 23: 82–85.
Wuis EW, Dirks MJ, Termond EF, Vree TB, Van der Kleijn E . Plasma and urinary excretion kinetics of oral baclofen in healthy subjects. Eur J Clin Pharmacol 1989; 37: 181–184.
Ashworth B . Preliminary trial of carisoprodol in multiple sclerosis. Practitioner 1964; 192: 540–542.
Ditunno Jr JF, Young W, Donovan WH, Creasey G . The international standards booklet for neurological and functional classification of spinal cord injury. American Spinal Injury Association. Paraplegia 1994; 32: 70–80.
Fawcett JW, Curt A, Steeves JD, Coleman WP, Tuszynski MH, Lammertse D et al. Guidelines for the conduct of clinical trials for spinal cord injury as developed by the ICCP panel: spontaneous recovery after spinal cord injury and statistical power needed for therapeutic clinical trials. Spinal Cord 2007; 45: 190–205.
Linacre JM, Heinemann AW, Wright BD, Granger CV, Hamilton BB . The structure and stability of the Functional Independence Measure. Arch Phys Med Rehabil 1994; 75: 127–132.
Cook KF, Teal CR, Engebretson JC, Hart KA, Mahoney JS, Robinson-Whelen S et al. Development and validation of Patient Reported Impact of Spasticity Measure (PRISM). J Rehabil Res Dev 2007; 44: 363–371.
Lechner HE, Frotzler A, Eser P . Relationship between self- and clinically rated spasticity in spinal cord injury. Arch Phys Med Rehabil 2006; 87: 15–19.
Johns MW . A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep 1991; 14: 540–545.
Hudgson P, Weightman D . Baclofen in the treatment of spasticity. BMJ 1971; 4: 15–17.
Nance PW, Bugaresti J, Shellenberger K, Sheremata W, Martinez-Arizala A . Efficacy and safety of tizanidine in the treatment of spasticity in patients with spinal cord injury. North American Tizanidine Study Group. Neurology 1994; 44: S44–S51.
Allergan Inc. Botox (OnabotulinumtoxinA) (Prescribing Information). Allergan Inc.: Irvine, CA, 2010.
Acknowledgements
We acknowledge the contributions of the following investigators, in addition to Dr Ayyoub, who enrolled the study patients: David F Apple, MD, Karen Ethans, MD, Sunil Hegde, MD, Amit Jha, MD, Ki H (Alex) Kim, MD, Maureen D Miner, MD, Edward C Nieshoff, MD, Colleen O’Connell, MD, and Atul Patel, MD. This study was funded by XenoPort Inc. Writing support was provided by XenoPort Inc.
Author information
Authors and Affiliations
Corresponding author
Ethics declarations
Competing interests
F Jacob Huff, Dan Chen, Amy Bian and David Stamler are employees of XenoPort Inc. Patricia W Nance and Alberto Martinez-Arizala have received compensation for consulting for XenoPort Inc. Ziyad Ayyoub received research support from XenoPort in relation to this study.
Additional information
Presented at the American Academy of Neurology 2010 Annual Meeting, April 10–17, 2010, Toronto, Ontario, Canada.
Rights and permissions
About this article
Cite this article
Nance, P., Huff, F., Martinez-Arizala, A. et al. Efficacy and safety study of arbaclofen placarbil in patients with spasticity due to spinal cord injury. Spinal Cord 49, 974–980 (2011). https://doi.org/10.1038/sc.2011.43
Received:
Revised:
Accepted:
Published:
Issue date:
DOI: https://doi.org/10.1038/sc.2011.43
Keywords
This article is cited by
-
A perspective on molecular signalling dysfunction, its clinical relevance and therapeutics in autism spectrum disorder
Experimental Brain Research (2022)
